fbpx
  • Home
  • Study Details
Not currently enrolling

MEtformin and Lorcaserin for WeighT Loss in Schizophrenia (MELT)

The purpose of this study is to test new pharmacologic strategies for weight loss in patients with schizophrenia, a population for which no current weight-loss treatments have gained widespread use. The goal is to recruit overweight people with schizophrenia to participate in a 52-week double-blind, randomized study to assess the efficacy and safety of lorcaserin/metformin combination treatment, lorcaserin monotherapy, and placebo on weight, body composition, and measures of glucose and lipid metabolism.

Age & Gender

  • 18 years ~ 65 years
  • Male, Female

Contact the Team

Location

Thank you for your interest, but this study is not currently enrolling.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Fred Jarskog
Psychiatry - NC Research Center

Study Topics

Eating, Nutrition, and Metabolism
Mental and Emotional Health
Obesity

IRB Number

15-1998

logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.